Indian regulators have ordered Sun Pharmaceutical Industries to stop manufacturing ophthalmic products at the Assam facility. This decision followed the discovery of failures in the company's quality management system. A joint inspection cited lapses that affected drug safety and quality, leading to a recall of several eye-drop brands. Significant adverse cases have raised concerns regarding product contamination, prompting further investigation.